Skip to main content
SpringerLink
Log in

Chronopharmacology of Anticancer Agents

  • Chapter
Physiology and Pharmacology of Biological Rhythms

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 125))

Abstract

Several strategies are aimed at increasing the selectivity of anticancer agents against cancer cells. Some are based on tumor cell biology: new drug development, resistance revertants, etc. Others are targeted at host cells: development of analogs with less toxicity than the parent drug, combinations of cytostatics without additive toxicities, scheduling and/or supportive care in order to increase chemotherapy tolerability, etc. (de Vita et al. 1993). A dose-efficacy relationship has been repeatedly established for cancer chemotherapy (Hryniuk 1988). For this reason, the chronobiology of normal cells has constituted the main basis for attempting to improve the therapeutic index of cytostatic drugs. It was expected that an increase in drug doses, and therefore therapeutic efficacy, would result from an adaptation of drug delivery to circadian rhythms (chronotherapy). We will examine the several steps which have led to the validation of the clinical relevance of chronotherapy in medical oncology that was anticipated more than 20 years ago (Haus et al. 1972; Halberg et al. 1973). Only the circadian aspects will be considered.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 429.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 549.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 549.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Adler S, Lang S, Langenmayer I et al (1994) Chronotherapy with 5-fluoruracil and folinic acid in advanced colorectal carcinoma. Results of a chronopharmacologic phase I trial. Cancer 73: 2905–2912

    PubMed  CAS  Google Scholar 

  • Advanced Colorectal Cancer Meta-Analysis Project (Piedbois P et al) (1992) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 10:896–903

    Google Scholar 

  • Aherne GW, English J, Burton N et al (1987) Chronopharmacokinetics and their relationship to toxicity and effect with reference to methotrexate, 6-mercaptopurine and morphine. Proceedings of the satellite symposia of the 4th European Conference of Clinical Oncology (ECCO-4), Madrid 1–4 Nov 1987, p 40

    Google Scholar 

  • Badran AF, Echave Llanos JM (1965) Persistence of mitotic circadian rhythm of a transplantable mammary carcinoma after 35 generations: its bearing on the success of treatment with endoxan. J Natl Cancer Inst 35: 285–290

    PubMed  CAS  Google Scholar 

  • Bailleul F, Lévi F, Reinberg A, Mathe G (1986) Interindividual differences in the cir- cadian hematologic time structure of cancer patients. Chronobiol Int 3: 47–54

    PubMed  CAS  Google Scholar 

  • Bailleul F, Lévi F, Metzger G et al (1987) Chronotherapy of advanced breast cancer with continuous doxorubicin infusion (C DOX I) via an implantable programmable device. Proc Am Assoc Cancer Res 28: 194 (abstract 771)

    Google Scholar 

  • Balis FM, Jeffries SL, Lange B et al (1989) Chronopharmacokinetics of oral methotrexate and 6-mercaptopurine: is there diurnal variation in the disposition of antileukemic therapy? Am J Pediatr Hematol Oncol 11: 324–326

    PubMed  CAS  Google Scholar 

  • Belanger PM, Labrecque G (1992) Biological rhythms in hepatic drug metabolism and biliary systems. In: Touitou Y, Haus E (eds) Biologic rhythms in clinical and laboratory medicine. Springer, Berlin Heidelberg New York, pp 403–409

    Google Scholar 

  • Benavides M (1991) Cancer avancé de l’ovaire: approche chronobiologique comme nouvelle stratégie du traitement et de la surveillance clinique et biologique. Thèse de doctorat en cancérologie, Université Paris X I

    Google Scholar 

  • Bertheault-Cvitkovic F, Lévi F, Soussan S et al (1993) Circadian-rhythm modulated chemotherapy with high-dose 5-fluorouracil: a pilot study in patients with pancreatic adenocarcinoma. Eur J Cancer 29A (13): 1851–1854

    Google Scholar 

  • Bertheault-Cvitkovic F, Jami A, Ithzaki M et al (1996) Biweekly dose intensification of circadian chronotherapy with 5-fluorouracil, folinic acid and oxaliplatin in patients with metastatic colorectal cancer. J Clin Oncol 14 (11) (in press)

    Google Scholar 

  • Bjarnason GA (1995) Clinical cancer chronotherapy trials: a review. J Infus Chemother 5: 29–37

    Google Scholar 

  • Bjarnason GA, Kerr IG, Doyle N et al (1993) Phase I study of 5-fluorouracil and leucovorin by a 14-day circadian infusion in metastatic adenocarcinoma patients. Cancer Chemother Pharmacol 33: 221–228

    PubMed  CAS  Google Scholar 

  • Boughattas NA, Lévi F, Hecquet B et al (1988) Circadian time dependence of murine tolerance for carboplatin. Toxicol Appl Pharmacol 96: 233–247

    PubMed  CAS  Google Scholar 

  • Boughattas N, Lévi F, Fournier C et al (1989) Circadian rhythm in toxicities and tissue uptake of 1,2-diaminocyclohexane (trans-1) oxalatoplatinum ( II) in mice. Cancer Res 49: 3362–3368

    Google Scholar 

  • Boughattas N, Lévi F, Fournier C et al (1990) Stable circadian mechanisms of toxicity of two platinum analogs (cisplatin and carboplatin) despite repeated dosages in mice. J Pharmacol Exp Ther 255: 672–679

    PubMed  CAS  Google Scholar 

  • Boughattas NA, Hecquet H, Fournier C et al (1994) Comparative pharmacokinetics of oxaliplatin (L-OHP) and carboplatin (CBDCA) in mice with reference to circadian dosing time. Biopharm Drug Dispos 15 (864): 1–13

    Google Scholar 

  • Buchi KN, Moore JG, Hrushesky WJM et al (1991) Circadian rhythm of cellular proliferation in the human rectal mucosa. Gastroenterology 101:410–415

    PubMed  CAS  Google Scholar 

  • Buchi KN, Moore JG, Hrushesky WJM et al (1991) Circadian rhythm of cellular proliferation in the human rectal mucosa. Gastroenterology 101:410–415

    PubMed  CAS  Google Scholar 

  • Burns ER, Beland SS (1984) Effect of biological time on the determination of the LD50 of 5-fluorouracil in mice. Pharmacology 28: 296–300

    PubMed  CAS  Google Scholar 

  • Cambar J, L’Azou B, Cal JC (1992) Chronotoxicology. In: Touitou Y, Haus E (eds) Biologic rhythms in clinical and laboratory medicine. Springer, Berlin Heidelberg New York, pp 138–150

    Google Scholar 

  • Canal P, Sqalli A, De Forni M et al (1991) Chronopharmacokinetics of doxorubicin in patients with breast cancer. Eur J Clin Pharmacol 40: 287–291

    PubMed  CAS  Google Scholar 

  • Caussanel JP, Lévi F, Brienza S et al (1990) Phase I trial of 5-day continuous infusion of oxaliplatinum at circadian-modulated vs constant rate. J Natl Cancer Inst 82: 1046–1050

    PubMed  CAS  Google Scholar 

  • Chollet P, Cure H, Garufi C et al Phase II trial with chronomodulated 5-fluorouracil (5-FU) and folinic acid (FA) in metastatic colorectal cancer. Proceedings of the 6th international conference on chronopharmacology and chronotherapy, Amelia Island, 5–9 July 1994, abstract VIIIb-4

    Google Scholar 

  • Codacci-Pisanelli G, van der Wilt C, Pinedo H et al (1995) Antitumor activity, toxicity and inhibition of thymidilate synthase of prolonged administration of 5-fluorouracil in mice. Eur J Cancer 31A: 1517–1525

    Google Scholar 

  • Damascelli B, Marchiano A, Spreafico C et al (1990) Circadian continuous chemotherapy of renal cell carcinoma with an implantable, programmable infusion pump. Cancer 66: 237–241

    PubMed  CAS  Google Scholar 

  • Deka AC (1975) Application of chronobiology to radiotherapy to tumours of the oral cavity. MD thesis, Postgraduate Institute of Medical Education and Research, Chandigarh, India

    Google Scholar 

  • Deprés-Brummer P, Lévi F, Di Palma M et al (1991) A phase I trial of 21-day continuous venous infusion of alpha-interferon at circadian rhythm modulated rate in cancer patients. J Immunother 10: 440–447

    PubMed  Google Scholar 

  • Deprés-Brummer P, Bertheault-Cvitkovic F, Lévi F et al (1995) Circadian rhythm modulated (CRM) chemotherapy of metastatic breast cancer with mitoxantrone, 5fluorouracil and folinic acid: preliminary results of a phase I trial. J Infus Che-mother. 5 (3, suppl 1): 144–147

    Google Scholar 

  • De Vita VT, Hellman S, Rosenberg SA (1993) Cancer. Principles and practice of oncology. Lippincott, Philadelphia

    Google Scholar 

  • Dexeus FH, Logothetis CJ, Sella A et al (1991) Circadian infusion of floxuridine in patients with metastatic renal cell carcinoma. J Urol 146: 709–713

    PubMed  CAS  Google Scholar 

  • Eksborg S, Stendahl U, Antila K (1989) Pharmacokinetics of 4’epiadriamycin after morning and afternoon intravenous administration. Med Oncol Tumor Pharmacother 6: 195–197

    PubMed  CAS  Google Scholar 

  • El Kouni MH, Naguib FNM, Park KS et al (1990) Circadian rhythm of hepatic uridine phosphorylase activity and plasma concentration of uridine in mice. Biochem Pharmacol 40: 2479–2485

    PubMed  Google Scholar 

  • English J, Marks V (1981) Diurnal variation in methylprednisolone metabolism in the rat. IRSC Med Sci 9: 721

    CAS  Google Scholar 

  • English J, Aherne GW, Marks V (1982) The effect of timing of a single injection on the toxicity of methotrexate in the rat. Cancer Chemother Pharmacol 9: 114–117

    PubMed  CAS  Google Scholar 

  • Fleming GF, Schilsky RL, Mick R et al (1994) Circadian variation of 5-fluorouracil (5-FU) and cortisol plasma levels during continuous-infusion 5-FU and leucovorin (LV) in patients with hepatic or renal dysfunction. Proc Am Soc Clin Oncol 13: 352 (abstract)

    Google Scholar 

  • Focan C (1979) Sequential chemotherapy and circadian rhythm in human solid tumors. Cancer Chemother Pharmacol 3: 197–202

    PubMed  CAS  Google Scholar 

  • Focan C (1985) Le rythme nycthéméral de la prolifération tumorale. Aspects expérimentaux et cliniques. Implication pour la chimiothérapie oncolytique. Thèse de doctorat en sciences biomédicales expérimentales, Université de Liège

    Google Scholar 

  • Focan C, Doalto L, Mazy V et al (1989) Vindesine en perfusion continue de 48 heures (suivie de cisplatine) dans le cancer pulmonaire avancé. Données chronopharmacocinétiques et efficacité clinique. Bull Cancer (Paris) 76: 909–912

    Google Scholar 

  • Focan C, Denis B, Kreutz F et al (1994) Ambulatory chronotherapy with 5-fluorouracil (5-FU), folinic acid (F) and carboplatin for advanced non small cell lung cancer (NSCLC). Proc Eur Soc Med Oncol Ann Oncol 1994 5 [Suppl 8]: P760 (abstract)

    Google Scholar 

  • Focan C, Denis B, Kreutz F et al (1995) Ambulatory chronotherapy with 5-fluorouracil, folinic acid and carboplatin for advanced non small cell lung cancer. A phase II feasibility trial. J Infus Chemother 5 (Suppl 1): 148–152

    PubMed  CAS  Google Scholar 

  • Garcia-Sainz M, Halberg F (1966) Mitotic rhythms in human cancer reevaluated by electronic computer programs. Evidence for chronopathology. J Natl Cancer Inst 37: 279–292

    Google Scholar 

  • Garufi C, Lévi F, Aschelter AM et al A Phase I trial of five day chronomodulated infusion of 5-fluorouracil and 1-folinic acid in patients with metastatic colorectal cancer (submitted for publication)

    Google Scholar 

  • Gautherie M, Gros C (1974) Circadian rhythm alteration of skin temperature in breast cancer. Chronobiologia 4: 1–17

    Google Scholar 

  • Giacchetti S, Gruia G, Itzhaki M et al (1995) Surgery after chronomodulated chemotherapy with 5-fluorouracil (5-FU), folinic acid (FA) and oxaliplatin (L-OHP) (chrono) allows long term survival of patients (pts) with unresectable colorectal liver metastases. Proc Am Assoc Clin Oncol 492 (abstract)

    Google Scholar 

  • Gonzalez RB, Sothern RB, Thatcher G et al (1989) Substantial difference in timing of murine circadian susceptibility to 5-fluorouracil and FUDR. Proc Am Assoc Cancer Res 30: A2452 (abstract)

    Google Scholar 

  • Halberg F, Haus E, Cardoso SS et al (1973) Toward a chronotherapy of neoplasia: tolerance of treatment depends upon host rhythms. Experientia 29: 909–934

    PubMed  CAS  Google Scholar 

  • Halberg F, Gupta BD, Haus E, Halberg E, Deka AC, Nelson W, Sothern RB, Cornelissen G, Klee J, Lakatua DJ, Scheving LE, Burns ER (1977) Steps toward a cancer chronopolytherapy. Proc. XIV and Congrès International de Thérapeutique, 810 Septembre 1977, Montpellier, France, pp 151–196

    Google Scholar 

  • Halberg F, Nelson W, Lévi F et al (1980) Chronotherapy of rat mammary cancer. Int J Chronobiol 7: 85–90

    PubMed  CAS  Google Scholar 

  • Harris B, Song R, Soong S et al (1989) Circadian variation of 5-fluorouracil catabolism in isolated perfused rat. Cancer Res 49: 6610–6614

    PubMed  CAS  Google Scholar 

  • Harris B, Song R, Soong S et al (1990) Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels:evidence for circadian variation of plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50: 197–201

    PubMed  CAS  Google Scholar 

  • Hassan M, Oberg G, Bekassy AN et al (1991) Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology. Cancer Chemother Pharmacol 28: 130–134

    PubMed  CAS  Google Scholar 

  • Haus E, Halberg F, Scheving L et al (1972) Increased tolerance of leukemic mice to arabinosylcytosine with schedule-adjusted to circadian system. Science 177: 80–82

    PubMed  CAS  Google Scholar 

  • Hecquet B, Sucche M (1986) Theoretical study of the influence of the circadian rhythm of plasma protein binding in cisplatin area under the curve. J Pharmacokinet Biopharmacol 14: 79–93

    CAS  Google Scholar 

  • Hecquet B, Meynadier J, Bonneterre J et al (1985) Time dependency in plasmatic protein binding of cisplatin. Cancer Treat Rep 69: 79–83

    PubMed  CAS  Google Scholar 

  • Hrushesky W (1985) Circadian timing of cancer chemotherapy. Science 228: 73–75

    PubMed  CAS  Google Scholar 

  • Hrushesky WJ, Lévi F, Halberg F et al (1982a) Circadian stage dependence of cisdiamminedichloroplatinum lethal toxicity in rats. Cancer Res 42: 945–949

    PubMed  CAS  Google Scholar 

  • Hrushesky WJM, Borch R, Lévi F (1982b) Circadian time dependence of cisplatin urinary kinetics. Clin Pharmacol Ther 32: 330–339

    PubMed  CAS  Google Scholar 

  • Hrushesky WJ, Haus E, Lakatua F et al (1983) Marker rhythms for cancer chrono-chemotherapy. In: Haus E, Kabat HF (eds) Chronobiology 1982–1983. Karger, Basel, pp 493–499

    Google Scholar 

  • Hrushesky W, von Roemeling R, Lanning RM et al (1990) Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma. J Clin Oncol 8: 1504–1513

    PubMed  CAS  Google Scholar 

  • Hrushesky WJM, Bjarnason GA (1993a) The application of circadian chronobiology to cancer chemotherapy. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer. Principles and practice on oncology. Lippincott, Philadelphia, pp 2666–2686

    Google Scholar 

  • Hrushesky WJM, Bjarnason GA (1993b) Circadian cancer therapy. J Clin Oncol 11: 1403–1417

    PubMed  CAS  Google Scholar 

  • Hryniuk WM (1988) The importance of dose intensity in the outcome of chemotherapy. In: De Vita VT, Holman S, Rosenberg SA (eds) Important advances in oncology. Lippincott, Philadelphia, pp 121–142

    Google Scholar 

  • Kerr DJ, Lewis C, O’Neil B et al (1990) The myelotoxicity of carboplatin is influenced by the time of its administration. Hematol Oncol 8: 59–63

    PubMed  CAS  Google Scholar 

  • Killman SA, Cronkite ZEP, Fliedner TM et al (1962) Mitotic indices of human bone marrow cells. 1. Number and cytologic distribution of mitoses. Blood 19: 743–750

    Google Scholar 

  • Klevecz R, Braly P (1987) Circadian and ultradian rhythms of proliferation in human ovarian cancer. Chronobiol Int 4 (4): 513–523

    PubMed  CAS  Google Scholar 

  • Klevecz R, Shymko R, Braly P (1987) Circadian gating of S phase in human ovarian cancer. Cancer Res 47: 6267–6271

    PubMed  CAS  Google Scholar 

  • Kodama M, Kodama T (1982) Influence of corticosteroid hormones on the therapeutic efficacy of cyclosphosphamide. Gann 73: 661–666

    PubMed  CAS  Google Scholar 

  • Koren G, Langevin AM, Olivieri N et al (1990) Diurnal variation in the pharmacokinetics and myelotoxicity of mercaptopurine in children with acute lymphocytic leukemia. Am J Dis Child 144: 1135–1137

    PubMed  CAS  Google Scholar 

  • Koren G, Ferrazini G, Sohl H et al (1992) Chronopharmacology of methotrexate pharmacokinetics in childhood leukemia. Chronobiol Int 9: 434–438

    PubMed  CAS  Google Scholar 

  • Langevin AM, Koren G, Soldin Si et al (1987) Pharmacokinetic case for giving 6mercaptopurine maintenance doses at night. Lancet 2: 505–506

    PubMed  CAS  Google Scholar 

  • Leichman CG, Fleming TR, Muggia FM et al (1995) Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group Study. J Clin Oncol 13: 1303–1311

    PubMed  CAS  Google Scholar 

  • Lévi F (1995) Chronochimiothérapie et intensité de dose. Bull Cancer 82 [Suppl 1]: 29s - 35s

    PubMed  Google Scholar 

  • Lévi F, Hrushesky W, Blomquist CH et al (1982a) Reduction of cis-diaminedichloroplatinum nephrotoxicity in rats by optimal circadian drug timing. Cancer Res 42: 950–955

    PubMed  Google Scholar 

  • Lévi F, Hrushesky WJM, Borch RF et al (1982b) Cisplatin urinary pharmacokinetics and nephrotoxicity: a common circadian mechanism. Cancer Treat Rep 66: 1933–1938

    PubMed  Google Scholar 

  • Lévi F, Mechkouri M, Roulon A et al (1985) Circadian rhythm in tolerance of mice for the new anthracycline analog 4’-0-tetrahydropyranyl-adriamycin ( THP ). Eur J Cancer Clin Oncol 21: 1245–1251

    PubMed  Google Scholar 

  • Lévi F, Metzger G, Bailleul F et al (1986) Circadian-varying plasma pharmacokinetics of doxorubicin ( DOX) despite continuous infusion at constant rate. Proc Am Assoc Cancer Res 27: 693

    Google Scholar 

  • Lévi F, Boughattas NA, Blazsek I (1988a) Comparative chronotoxicity of anticancer agents and related mechanisms. Annu Rev Chronopharmacol 4: 283–331

    Google Scholar 

  • Lévi F, Blazsek I, Ferle-Vidovic A (1988b) Circadian and seasonal rhythms in murine bone marrow colony-forming cells affect tolerance for the anticancer agent 4’-0tetrahydropyranyladriamycin ( THP ). Exp Hematol 16: 696–701

    Google Scholar 

  • Lévi F, Benavides M, Chevelle C et al (1990) Chemotherapy of advanced ovarian cancer with 4’-0-tetrahydropyranyl adriamycin (THP) and cisplatin: a phase II trial with an evaluation of circadian timing and dose intensity. J Clin Oncol 8: 705–714

    PubMed  Google Scholar 

  • Lévi F, Misset JL, Brienza S et al (1992) A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 69: 893–900

    PubMed  Google Scholar 

  • Lévi F, Brienza S, Metzger G et al (1993a) Implications of chronobiology for 5-fluorouracil (5-FU) efficacy. In: Rustum YM (ed) Novel approaches to selective treatments of human solid tumors: laboratory and clinical correlation. Plenum, New York, pp 169–186

    Google Scholar 

  • Lévi F, Perpoint B, Garufi C et al (1993b) Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer 29 (9): 1280–1284

    Google Scholar 

  • Lévi F, Bourin P, Deprés-Brummer P et al (1994a) Chronobiology of the immune system: implication for the delivery of therapeutic agents. Clin Immunother 2 (1): 53–64

    Google Scholar 

  • Lévi F, Tampellini M, Metzger G et al (1994b) Circadian changes in mitoxantrone toxicity in mice:relationship with plasma pharmacokinetics. Int J Cancer 59: 543–547

    Google Scholar 

  • Lévi F, Zidani R, Vannetzel JM et al (1994c) Chronomodulated versus fixed infusion rate delivery of ambulatory chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with colorectal cancer metastases. A randomized multiinstitutional trial. J Nati Cancer Inst 86: 1608–1617

    Google Scholar 

  • Lévi F, Zidani R, Dipalma M, International Organization for Cancer Chronotherapy (IOCC) (1994d) Improved therapeutic index through ambulatory circadian rhythmic delivery (CRD) of high dose 3-drug chemotherapy in a randomized phase III multicenter trial. Proc Am Soc Clin Oncol 13: 574 (abstract)

    Google Scholar 

  • Lévi F, Giacchetti S, Adam R, International Organization for Cancer Chronotherapy (1995a) Chronomodulation of chemotherapy against metastatic colorectal cancer. Eur J Cancer 31A: 1264–1270

    Google Scholar 

  • Lévi F, Soussan A, Adam R et al (1995b) A Phase I-II trial of five-day continuous intravenous infusion of 5-fluorouracil delivered at circadian rhythm modulated rate in patients with metastatic colorectal cancer. J Infus Chemother 5 (Suppl 1): 153–158

    PubMed  Google Scholar 

  • Lévi F, Zidani R, Vannetzel JM et al (1995c) Chronomodulated versus flat infusion of 5-fluorouracil (5-FU), folinic acid (FA) and oxaliplatin (L-OHP) against metastatic colorectal cancer (MCC) in 2 consecutive European randomized multicenter trials (T). Proc Am Assoc Clin Oncol 493 (abstract)

    Google Scholar 

  • Lévi F, Dogliotti L, Perpoint B et al (1995d) Ambulatory intensified 4-day (d) every 2 weeks chronotherapy with oxaliplatin (L-OHP), 5-fluorouracil (5-FU) and folinic acid (FA) in patients (pts) with metastatic colorectal cancer (MCC). Proc Am Soc Clin Oncol 568 (abstract)

    Google Scholar 

  • Li XM, Metzger G, Filipski E et al Pharmacologic modulation of reduced glutathione (GSH) circadian rhythms by buthionine sulfoximine (BSO): relationship with cisplatin (CDDP) toxicity in mice (submitted for publication)

    Google Scholar 

  • Malmary-Nebot M, Labat C, Casanovas A et al (1985) Aspect chronobiologique de l’action du methotréxate sur la dihydrofolate réductase. Ann Pharm Fr 43: 337–343

    PubMed  CAS  Google Scholar 

  • Martineau-Pivoteau N, Lévi F, Cussac C (in press) Circadian rhythm in toxic effects of cystemustine and its relationship with alkytransferase activity. Int J Cancer Mauer AM (1965) Diurnal variation of proliferative activity in the human bone marrow. Blood 26:1–7

    Google Scholar 

  • Metzger G, Massari C, Etienne MC et al (1994) Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in cancer patients. Clin Pharmacol Ther 56: 190–201

    PubMed  CAS  Google Scholar 

  • Mormont C, Boughattas N, Lévi F et al (1989) Mechanisms of circadian rhythms in the toxicity and the efficacy of anticancer drugs: relevance for the development of new analogs. In: Lemmer B (ed) Chronopharmacology: cellular and biochemical interactions. Dekker, New York, pp 395–437

    Google Scholar 

  • Naguib FNM, Soong SJ, El Kouni MH (1993) Circadian rhythm of orotate phosphoribosyltransferase, pyrimidine nucleoside phosphorylases and dihydrouracil dehydrogenase in mouse liver. Biochem Pharmacol 45: 667–673

    PubMed  CAS  Google Scholar 

  • Nowakowska-Dulawa E (1990) Circadian rhythm in 5-fluorouracil (FU) pharmacokinetics and tolerance. Chronobiologia 17: 27–35

    PubMed  CAS  Google Scholar 

  • Perpoint B, Le Bousse-Kerdiles C, Clay D et al (1995) In vitro chronopharmacology of recombinant mouse IL-3, mouse GM-CSF and human G-CSF on murine myeloid progenitor cells. Exp Hematol 23: 362–368

    PubMed  CAS  Google Scholar 

  • Peters GJ, Van Dijk J, Nadal JC, Van Groeningen CS, Lankelma J, Pinedo HM (1987) Diurnal variation in the therapeutic efficacy of 5-fluorouracil against murine colon cancer. In Vivo 1: 113–118

    Google Scholar 

  • Petit E, Milano G, Lévi F et al (1988) Circadian varying plasma concentration of 5-FU during 5-day continuous venous infusion at constant rate in cancer patients. Cancer Res 48: 1676–1679

    PubMed  CAS  Google Scholar 

  • Rivard G, Infante-Rivard C, Hoyeux C et al (1985) Maintenance chemotherapy for childhood acute lymphoblastic leukemia: better in the evening. Lancet I: 1264–1266

    Google Scholar 

  • Robinson BA, Begg EJ, Colls BM et al (1989) Circadian pharmacokinetics of methotrexate. Cancer Chemother Pharmacol 24: 397–399

    PubMed  CAS  Google Scholar 

  • Sabbag R, Sunderland M, Leclerc JM et al (1993) Chronopharmacokinetic of a 48-hour continuous infusion of doxorubicin to children with acute lymphoblastic leukemia. Proceedings of the XXIst conference of the International Society of Chronobiology, abstract XI - 5

    Google Scholar 

  • Scheving LE, Haus E, Kuhl JEW et al (1976) Different laboratories closely reproduce characteristics of circadian rhythm in tolerance of mice for arabinofuranosylcytosine. Cancer Res 36: 1133–1137

    PubMed  CAS  Google Scholar 

  • Scheving LE, Burns ER, Pauly JE et al (1977) Survival and cure of leukemic mice after circadian optimization of treatment with cyclophosphamide and 1–3-arabinofuranosylcytosine. Cancer Res 37: 3648–3655

    PubMed  CAS  Google Scholar 

  • Scheving LE, Burns ER, Halberg F et al (1980a) Combined chronochemotherapy of L1210 leukemic mice using ß-D-arabinofuranosylcytosine, cyclophosphamide, vincristine, methylprednisolone and cis-diaminedichloroplatinum. Chronobiologia 17 (1): 33–40

    Google Scholar 

  • Scheving LE, Burns ER, Pauly JE, Halberg F (1980b) Circadian bioperiodic response of mice bearing advanced L1210 leukemia to combination therapy with adriamycin and cyclophosphamide. Cancer Res 40: 1511–1515

    PubMed  CAS  Google Scholar 

  • Smaaland R, Laerum OD, Lote K et al (1991a) DNA synthesis in human bone marrow is circadian stage dependent. Blood 77: 2603–2611

    PubMed  CAS  Google Scholar 

  • Smaaland R, Svardal AM, Lote K et al (1991b) Glutathione content in human bone marrow and circadian stage relation to DNA synthesis. J Natl Cancer Inst 83: 1092–1098

    PubMed  CAS  Google Scholar 

  • Smaaland R, Laerum OD, Sothern RB et al (1992a) Colony-forming unit-granulocytemacrophage and DNA synthesis of human bone marrow are circadian stage-dependent and show covariation. Blood 79: 2281–2287

    PubMed  CAS  Google Scholar 

  • Smaaland R, Abrahamsen JF, Svardal AM (1992b) DNA cell cycle distribution and glutathione ( GSH) content according to circadian stage in bone marrow of cancer patients. Br J Cancer 66: 39–45

    Google Scholar 

  • Smaaland R, Lote K, Sothern RB et al (1993) DNA synthesis and ploidy in non-Hodgkin’s lymphomas demonstrate variation depending on circadian stage of cell sampling. Cancer Res 53: 3129–3138

    PubMed  CAS  Google Scholar 

  • Sothern R, Lévi F, Haus E et al (1989) Control of a murine plasmacytoma with doxorubicin-cisplatin: dependence on circadian stage of treatment. J Natl Cancer Inst 81: 135–145

    PubMed  CAS  Google Scholar 

  • Squalli A, Oustrin J, Houin G et al (1989) Clinical chronopharmacokinetics of doxorubicin ( DXR ). Annu Rev Chronopharmacol 5: 393–396

    Google Scholar 

  • Stoll BA, Burch W (1968) Surface detection of circadian rhythm in 32p content of cancer of the breast. Cancer 21: 193–196

    PubMed  CAS  Google Scholar 

  • Tahti E (1956) Studies of the effect of X-irradiation on 24 hour variations in the mitotic activity in human malignant tumors. Acta Pathol Microbiol Scand 117: 1–61

    Google Scholar 

  • Tampellini M, Filipski E, Vrignaud P et al (1995) Circadian dosing time dependency of docetaxel toxicity in mice: implication for antitumor efficacy. Proc Am Assoc Cancer Res 36: 2713 (abstract)

    Google Scholar 

  • Thiberville L, Compagnon P, Moore N et al (1992) Accumulation plasmatique du 5fluorouracile chez l’insuffisant respiratoire. Rev Mal Respir 111 (abstract)

    Google Scholar 

  • Touitou Y, Lévi F, Bogdan A et al (1995) Circadian desynchronization of blood variables in patients with metastatic breast cancer. Role of prognostic factors. J Cancer Res Clin Oncol 121: 181–188

    PubMed  CAS  Google Scholar 

  • Vassal G, Challine D, Koscielny S et al (1993) Chronopharmacology of high-dose busulfan in children and its relationship with liver toxicity. Cancer Res 53: 1534–1537

    PubMed  CAS  Google Scholar 

  • Von Roemeling R, Hrushesky W (1989) Circadian patterning of continuous floxouridine infusion reduces toxicity and allows higher dose intensity in patients with widespread cancer. J. Clin. Oncol., 7: 1710–1719

    Google Scholar 

  • Von Roemeling R, Hrushesky WJM (1990) Determination of the therapeutic index of floxuridine by its circadian infusion pattern. J Natl Cancer Inst 82: 386–393

    Google Scholar 

  • Voutilainen A (1953) Über die 24-Stunden-Rhythmik der Mitozfrequenz in malignen Tumoren. Acta Pathol Microbiol Scand [Suppl] 99: 1–104

    CAS  Google Scholar 

  • Warnakulasuriya KAAS, MacDonald DG (1993) Diurnal variation in labelling index in human buccal epithelium. Arch Oral Biol 38 (12): 1107–1111

    PubMed  CAS  Google Scholar 

  • Zhang R, Lu Z, Liu T et al (1993) Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes: possible relevance to fluoropyrimidine chemotherapy. Cancer Res 53: 2816–2822

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. F. Lévi
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. School of Pharmacy and Pharmacology, University of Bath, Claverton Down, BA1 7AY, Bath, UK

    Peter H. Redfern BPharm, PhD

  2. Instituts für Pharmakologie und Toxikologie Fakultät für klinische Medizin Mannheim, Universität Heidelberg, Maybachstr. 14-16, 68169, Mannheim, Germany

    B. Lemmer (Direktor) (Direktor)

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Lévi, F. (1997). Chronopharmacology of Anticancer Agents. In: Redfern, P.H., Lemmer, B. (eds) Physiology and Pharmacology of Biological Rhythms. Handbook of Experimental Pharmacology, vol 125. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-09355-9_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-09355-9_11

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-08265-8

  • Online ISBN: 978-3-662-09355-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation